Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2020-10-30, Stock:LLY, The news for the past five days is as follows:
2020-10-23: NEWS1: Remdesivir Gets FDA Approval. What It Means for Gilead Stock and Vaccine Makers..NEWS2: Remdesivir ‘is not a knock out punch’ but it does help patients ‘recover quicker’: doctor.NEWS3: Pharmaceutical companies ‘are doing a good job’ with efficacy and transparency: physician.NEWS4: Roche (RHHBY) Inks Deal to Develop Oral Coronavirus Treatment.NEWS5: Benzinga's Top Upgrades, Downgrades For October 23, 2020.NEWS6: New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status.NEWS7: Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus.
2020-10-26: NEWS1: Eli Lilly antibody drug fails in a COVID-19 study; other studies go on.NEWS2: Were Hedge Funds Right About Eli Lilly and Company (LLY)?.
2020-10-27: NEWS1: Analyst Report: Eli Lilly and Company.NEWS2: These 2 Big Earnings Reports Led Stock Markets Lower Tuesday.NEWS3: Eli Lilly and Company (LLY) Q3 2020 Earnings Call Transcript.NEWS4: ‘Someone, somewhere in the U.S. is getting overwhelmed’ with the rising numbers of covid cases: UC Davis Health.NEWS5: US STOCKS-S&P 500, Dow slip on worries about earnings, U.S. stimulus outlook.NEWS6: Eli Lilly Earnings Miss, Covid-19 Treatment Fails In Trials.NEWS7: LLY Stock Falls As Eli Lilly Earnings Miss, Covid-19 Treatment Fails In Trials.NEWS8: Coronavirus Latest: Tuesday, October 27.NEWS9: Eli Lilly slumps after earnings miss, paused COVID-19 antibody trial.NEWS10: Why Eli Lilly Stock Is Down Today.NEWS11: Eli Lilly strikes optimistic tone on COVID-19 therapy after trial failure.NEWS12: Pfizer’s Covid-19 vaccine doesn’t add a ‘tremendous amount’ to the company’s valuation: Analyst.NEWS13: Analyst Report: Eli Lilly and Company.NEWS14: Lilly (LLY) Q3 Earnings & Revenues Lag Estimates, Stock Down.NEWS15: Stop Waiting on New Covid-19 Treatments. Wear a Mask..NEWS16: CAT earnings show slow in demand, 3M sees strong earnings on safety equipment sales.NEWS17: Eli Lilly (LLY) Q3 Earnings and Revenues Miss Estimates.NEWS18: US STOCKS-S&P 500 flat after Monday's selloff as focus turns to corporate earnings.NEWS19: Stuck Americans Spend on DIY Projects and Crocs: Earnings Wrap.NEWS20: NIH Ends Clinical Trial of Eli Lily's Coronavirus Antibody Therapy Candidate.NEWS21: Eli Lilly Misses Q3 Profit Forecast As Trulicity Sales Slow, COVID R&D Spend Rises.NEWS22: The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings.NEWS23: Why Eli Lilly’s September Earnings Disappointed Wall Street.NEWS24: Recap: Eli Lilly Q3 Earnings.NEWS25: Eli Lilly shares slump premarket after earnings miss.NEWS26: Eli Lilly strikes optimistic tone on COVID-19 therapy after trial failure.NEWS27: Lilly profit hit by COVID-19 drug development costs, weak demand.NEWS28: Wall Street Opens Mixed as Virus Focuses Minds on Weak Results; Dow Down 32 Pts.NEWS29: Eli Lilly Ends Covid-19 Trial In Hospitalized Patients On Disappointing Data.NEWS30: Stimulus Gone, Earnings Deluge, AMD/Xilinx Deal - What's Moving Markets.NEWS31: PRESS DIGEST- New York Times business news - Oct 27.NEWS32: NIAID Study Finds Eli Lilly's Antibody Drug Unhelpful For Hospitalized COVID-19 Patients.NEWS33: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eli Lilly and Company - LLY.
2020-10-28: NEWS1: Study: Lilly's experimental COVID-19 drug may reduce hospitalizations.NEWS2: Study: Lilly's experimental COVID-19 drug may reduce hospitalizations.NEWS3: Amgen Earnings, Sales Top Wall Street Views; Hikes Earnings Guidance.NEWS4: Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatients published in New England Journal of Medicine.NEWS5: Amgen Reports Stronger-Than-Expected Q3 Earnings; Revenue Gains 12%.NEWS6: Eli Lilly Inks Covid-19 Treatment Supply Deal With U.S. Despite Drug's Recent Failure.NEWS7: ‘We could see daily averages well over 1,000 deaths per day’ going into winter: doctor.NEWS8: Coronavirus Latest: Wednesday, October 28.NEWS9: Coronavirus update: Case surges spark fear in markets globally; experts wary about a vaccine by the end of the year.NEWS10: Company News for Oct 28, 2020.NEWS11: Morning Bell With Jim Cramer: Buy Eli Lilly.NEWS12: Move Over, Regeneron! Operation Warp Speed Has a New Partner.NEWS13: Eli Lilly, U.S. in Accord for Covid-19 Antibody.NEWS14: U.S. strikes deal with Lilly for potential COVID-19 antibody drug.NEWS15: The Daily Biotech Pulse: Sanofi-GlaxoSmithKline To Supply 200M Doses To COVID-19 Vaccine Alliance, Gilead Earnings, Biodesix Debuts.NEWS16: Lilly signs deal with U.S. government for still-investigational COVID-19 antibody drug.NEWS17: Surviving in This Environment, Shaky Recovery, Lilly and Pfizer Setbacks.NEWS18: Eli Lilly signs deal with U.S. for 300,000 vials of potential COVID-19 drug.NEWS19: Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19.NEWS20: What's Next for Eli Lilly's COVID-19 Antibodies?.NEWS21: What's Next for Eli Lilly's COVID-19 Antibodies?.
2020-10-29: NEWS1: Regeneron Posts Positive Data For Covid-19 Treatment; Lung Cancer Drug Advances.NEWS2: ETFs to Shine on Lilly's U.S. Deal for Coronavirus Antibody.NEWS3: Coronavirus Latest: Thursday, October 29.NEWS4: IBD 50 Stocks To Watch: Pharma That Treated Trump Is Building Base.NEWS5: Is Eli Lilly and Company (NYSE:LLY) Trading At A 35% Discount?.NEWS6: Incyte (INCY) to Post Q3 Earnings: Will Jakafi Drive Results?.NEWS7: Amgen (AMGN) Losing Altitude Despite Strong Quarter.NEWS8: Column: While decrying 'socialized medicine,' Trump spends billions on COVID drugs.NEWS9: New Data at EADV 2020 Confirm Taltz® (ixekizumab) Demonstrates Sustained Long-Term Efficacy in Patients with Psoriasis and Psoriatic Arthritis.NEWS10: Eli Lilly Strikes $375M Covid-19 Antibody Supply Deal With US Government.NEWS11: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eli Lilly and Company - LLY.

Answer: Decrease